Biocitech Life Science Park Welcomes Chem-X-Infinity and Spectralys Innovation
News Nov 25, 2008
Biocitech, the Paris life science technology park, announces that two new companies, Chem-X-Infinity and Spectralys Innovation, have become the park's 23rd and 24th residents. The new companies bring new strengths in chemistry and consulting to the life science industry.
Chem-X-Infinity sarl is specialized in the automated synthesis of libraries of organic molecules for the pharmaceutical and agrochemical industries. Founded in 2008, this company uses standard medicinal chemistry filters and molecular modeling tools including virtual screening and docking, to identify molecules whose chemical structure appears to be of interest.
Chem-X-Infinity sells from catalog on a semi-exclusive basis, offering to design exclusive focused chemical libraries. Chem-X-Infinity's products offer in vitro biological screening to accelerate the process of finding new active molecules.
"Biocitech is delighted to welcome Chem-X-Infinity and Spectralys Innovation, two companies who boost our activities in chemistry and R&D," said Biocitech CEO, Jacques Lhomel. "The three new arrivals this fall demonstrate our success and our drive for expansion, generating the need to double the area of the park. Expansion work is planned to start at the end of 2009 for completion in 2011."
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Synthesis of Drug-Like Molecules Simplified Using New Cross-Coupling MethodNews
Researchers have designed a new molecule-building method. The technique, described recently in the journal Science, paves the way toward other new chemical reactions and facilitates the synthesis of pharmaceutically-relevant molecules.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
World Congress on Advances in Addiction Science and Medicine
Sep 24 - Sep 25, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018